Compare AbCellera Biologics Inc (ABCL) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Williams-Sonoma, Inc. — how do they compare? AbCellera Biologics Inc trades at $7.11 (market cap $2.35B), while Williams-Sonoma, Inc. trades at $218.23 (market cap $26.36B). The key difference: Williams-Sonoma, Inc. is far larger — about 11.2× AbCellera Biologics Inc's market cap, and Williams-Sonoma, Inc. pays a 1.36% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | WSM | |
|---|---|---|
Market Cap | $2.35B | $26.36B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $240.06 |
52-Week Low | $2.78 | $163.62 |
Enterprise Value | $1.99B | $27.20B |
Dividend Yield | — | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Williams-Sonoma (WSM) trades at $222.49, down 2.22% today, with a bullish technical signal and strong profitability metrics including 54.01% ROE and 13.81% net margin. The stock has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $2.03. Recent news highlights brand collaborations and dividend declarations, while cash flow trends show operational strength despite net outflows in 2025.
WSM presents a mixed outlook with robust fundamentals and analyst consensus leaning hold (60.72%), but risks include competitive pressures and macroeconomic sensitivity. The current price sits above the $215.50 consensus target, suggesting limited near-term upside despite strong operational performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
